Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 9Thoracic 4Dermatologic 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Sarcoma 1Recurrence 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 48Bevacizumab 29Carmustine 17Erlotinib Hydrochloride 16Radiotherapy 14Irinotecan 14Surgical Procedures, Operative 10Sirolimus 10Imatinib Mesylate 10Carboplatin 10Sorafenib 9O(6)-benzylguanine 9Filgrastim 9Etoposide 8temsirolimus 7sargramostim 7Radiosurgery 7Radiation 7Procarbazine 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7aldesleukin 6Topotecan 6Thalidomide 6Vorinostat 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Hydroxyurea 5Gefitinib 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Spermine Synthase × Sarcoma × Clear all
NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Lumos Pharma

Phase 1/2 Completed
160 enrolled 21 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡